The detailed information for PTAB case with proceeding number PGR2025-00032 filed by Neurocrine Biosciences, Inc. against Spruce Biosciences, Inc. on Feb 10, 2025. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number
PGR2025-00032
Filing Date
Feb 10, 2025
Petitioner
Neurocrine Biosciences, Inc.
Respondent
Spruce Biosciences, Inc.
Status
Pending
Respondent Application Number
18307718
Respondent Tech Center
1600
Respondent Patent Number
12115166

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.


Document NameFiling DateCategoryFiling Party

Alert me when new update on this case

Patent Owner's Preliminary Response

Jul 8, 2025PAPERPATENT OWNER

EX2001 - Statutory Disclaimer filed 05-07-2025

Jul 8, 2025EXHIBITPATENT OWNER

Notice: Referral to Board Panel

Jun 11, 2025PAPERBOARD

Notice: Notice filing date accorded

Apr 8, 2025PAPERBOARD

Notice: Mandatory Notice

Mar 3, 2025PAPERPATENT OWNER

Notice: Power of Attorney

Mar 3, 2025PAPERPATENT OWNER

U.S. Patent No. 12,115,166 to Alexis Howerton, et al. (“the ’166 patent”)

Feb 10, 2025EXHIBITPETITIONER

U.S. Prosecution History of the ’166 Patent Part 1 of 6

Feb 10, 2025EXHIBITPETITIONER

U.S. Prosecution History of the ’166 Patent Part 2 of 6

Feb 10, 2025EXHIBITPETITIONER

U.S. Prosecution History of the ’166 Patent Part 3 of 6

Feb 10, 2025EXHIBITPETITIONER

U.S. Prosecution History of the ’166 Patent Part 4 of 6

Feb 10, 2025EXHIBITPETITIONER

U.S. Prosecution History of the ’166 Patent Part 5 of 6

Feb 10, 2025EXHIBITPETITIONER

U.S. Prosecution History of the ’166 Patent Part 6 of 6

Feb 10, 2025EXHIBITPETITIONER

Final Written Decision, Paper 64, PGR2021-00088 (PTAB Nov. 27, 2024)

Feb 10, 2025EXHIBITPETITIONER

U.S. Patent Application Publication No. 2017/0020877 to Grigoriadis et al.

Feb 10, 2025EXHIBITPETITIONER

Final Written Decision, Paper 62, PGR2022-00025 (PTAB Nov. 26, 2024).

Feb 10, 2025EXHIBITPETITIONER

Turcu et al., “Single-Dose Study of a Corticotropin-Releasing"-Turcu 2016

Feb 10, 2025EXHIBITPETITIONER

Auchus et al., “Crinecerfont Lowers Elevated Hormone Markers"-Auchus 2021

Feb 10, 2025EXHIBITPETITIONER

Director Decision, Paper 16, PGR2021-00088 (Aug. 4, 2023)

Feb 10, 2025EXHIBITPETITIONER

Director Decisions, Paper 15, PGR2022-00025 (Aug. 4, 2023)

Feb 10, 2025EXHIBITPETITIONER

U.S. Patent No. 8,030,304 to Chen et al. (“Chen”)

Feb 10, 2025EXHIBITPETITIONER

Speiser et al., “Congenital Adrenal Hyperplasia"-Speiser 2010

Feb 10, 2025EXHIBITPETITIONER

Turcu & Auchus, The Next 150 Years of Congenital Adrenal Hyperplasia

Feb 10, 2025EXHIBITPETITIONER

El Maouche “Congenital Adrenal Hyperplasia,” - El Maouche 2017

Feb 10, 2025EXHIBITPETITIONER

Merke & Bornstein “Congenital Adrenal Hyperplasia,”-Merke & Bornstein 2005

Feb 10, 2025EXHIBITPETITIONER

Speiser "Congenital Adrenal Hyperplasia..."-Speiser 2018

Feb 10, 2025EXHIBITPETITIONER

Fahmy “Structure and Function of Small Non-Peptide CRF..."-Fahmy 2017

Feb 10, 2025EXHIBITPETITIONER

Griebel et al., J. Pharmacol. Exp. Ther. - Griebel 2002

Feb 10, 2025EXHIBITPETITIONER

Gully et al., J. Pharmacol. Exp. Ther., Gully 2002

Feb 10, 2025EXHIBITPETITIONER

Merke & Cutler “New Ideas for Medical Treatment..."-Merke & Cutler 2001

Feb 10, 2025EXHIBITPETITIONER

Merk “Future Directions in the Study and Management..."-Merke 2002

Feb 10, 2025EXHIBITPETITIONER

Trapp, “Congenital adrenal hyperplasia: an update in children,”

Feb 10, 2025EXHIBITPETITIONER

Merke & Auchus “Congenital Adrenal Hyperplasia..." Merke & Auchus 2020

Feb 10, 2025EXHIBITPETITIONER

Turcu & Auchus “Novel Treatment Strategies" Turcu & Auchus 2016

Feb 10, 2025EXHIBITPETITIONER

Webb & Krone “Current and Novel Approaches to Children"-Webb & Krone 2015

Feb 10, 2025EXHIBITPETITIONER

Neurocrine March 20, 2021, Press Release

Feb 10, 2025EXHIBITPETITIONER

Nella “A Phase 2 Study of Continuous Subcutaneous Hydrocortisone..."

Feb 10, 2025EXHIBITPETITIONER

Williams, “Corticotropin-Releasing Factor 1 Receptor ..." Williams 2013

Feb 10, 2025EXHIBITPETITIONER

Zorrilla & Koob 2010

Feb 10, 2025EXHIBITPETITIONER

Kehne & Cain “Therapeutic Utility of Non-Peptidic CRF1" - Kehne & Cain 2010

Feb 10, 2025EXHIBITPETITIONER

Deore “The Stages of Drug Discovery and Development Process,”

Feb 10, 2025EXHIBITPETITIONER

National Center for Biotechnology Information (2025)

Feb 10, 2025EXHIBITPETITIONER

U.S. Provisional Application Serial No. 62/545,406

Feb 10, 2025EXHIBITPETITIONER

U.S. Patent No. 10,849,908 to Alexis Howerton, et al.

Feb 10, 2025EXHIBITPETITIONER

U.S. Patent No. 11,007,201 B2 to Alexis Howerton, et al.

Feb 10, 2025EXHIBITPETITIONER

Yamaguchi “Approval success rates of drug candidates based on target..."

Feb 10, 2025EXHIBITPETITIONER

Sarafoglou “Interpretation of Steroid Biomarkers in 21..." Sarafoglou 2023

Feb 10, 2025EXHIBITPETITIONER

Sarafoglou “Tildacerfont in Adults With Classic..." Sarafoglou 2021

Feb 10, 2025EXHIBITPETITIONER

Spruce March 25, 2019, Press Release

Feb 10, 2025EXHIBITPETITIONER

Spruce March 13, 2024, Press Release

Feb 10, 2025EXHIBITPETITIONER

Spruce December 10, 2024, Press Release

Feb 10, 2025EXHIBITPETITIONER

Turcu & Auchus “Adrenal Steroidogenesis and Congenital..." Turcu 2015a

Feb 10, 2025EXHIBITPETITIONER

Mallappa & Merke “Management challenges and therapeutic advances in..."

Feb 10, 2025EXHIBITPETITIONER

Auchus “Crinecerfont Lowers Elevated Hormone Markers..." Auchus 2022

Feb 10, 2025EXHIBITPETITIONER

Claahsen-van der Grinten “Congenital Adrenal Hyperplasia..."

Feb 10, 2025EXHIBITPETITIONER

Guidance for Industry, Q1A(R2) Stability Testing of New Drug Substances...

Feb 10, 2025EXHIBITPETITIONER

“Guidance for Industry, Q1E Evaluation of Stability Data,”

Feb 10, 2025EXHIBITPETITIONER

Auchus “Phase 3 Trial of Crinecerfont..." Auchus 2024

Feb 10, 2025EXHIBITPETITIONER

Sarafoglou "Phase 3 Trial of Crinecerfont..." Sarafoglou et al. 2024

Feb 10, 2025EXHIBITPETITIONER

Product Quality Review: CRENESSITY (Crinecerfont)

Feb 10, 2025EXHIBITPETITIONER

Neurocrine July 1, 2024, Press Release

Feb 10, 2025EXHIBITPETITIONER

Dec. 13, 2024, Neurocrine Press Release

Feb 10, 2025EXHIBITPETITIONER

National Center for Biotechnology Information (2025), CID 134694266

Feb 10, 2025EXHIBITPETITIONER

Petition for Post Grant Review of U.S. Patent No. 10,849,908

Feb 10, 2025EXHIBITPETITIONER

Pet Reply to POR, Paper 32, PGR2021-00088 (June 20, 2024)

Feb 10, 2025EXHIBITPETITIONER

Petition for Post Grant Review of U.S. Patent No. 11,007,201

Feb 10, 2025EXHIBITPETITIONER

Pet Reply to POR, Paper 30, PGR2022-00025 (June 20, 2024).

Feb 10, 2025EXHIBITPETITIONER

Sertkaya “Key cost drivers of pharmaceutical trials in the United States"

Feb 10, 2025EXHIBITPETITIONER

Spierling & Zorrilla, "Don’t stress about CRF: Assessing..."

Feb 10, 2025EXHIBITPETITIONER

Notice: Power of Attorney

Feb 10, 2025PAPERPETITIONER

Declaration of Maya Lodish, M.D.

Feb 10, 2025EXHIBITPETITIONER

Declaration of David E. Bugay, Ph.D.

Feb 10, 2025EXHIBITPETITIONER

Petition: as filed

Feb 10, 2025PAPERPETITIONER